nature medicine l e t t e r S Mechanical allodynia, induced by normally innocuous lowthreshold mechanical stimulation, represents a cardinal feature of neuropathic pain. Blockade or ablation of high-threshold, small-diameter unmyelinated group C nerve fibers (C-fibers) has limited effects on mechanical allodynia [1] [2] [3] [4] . Although large, myelinated group A fibers, in particular A-fibers, have previously been implicated in mechanical allodynia [5] [6] [7] , an A-fiber-selective pharmacological blocker is still lacking. Here we report a new method for targeted silencing of A-fibers in neuropathic pain. We found that Toll-like receptor 5 (TLR5) is co-expressed with neurofilament-200 in large-diameter A-fiber neurons in the dorsal root ganglion (DRG). Activation of TLR5 with its ligand flagellin results in neuronal entry of the membrane-impermeable lidocaine derivative QX-314, leading to TLR5-dependent blockade of sodium currents, predominantly in A-fiber neurons of mouse DRGs. Intraplantar co-application of flagellin and QX-314 (flagellin/QX-314) dose-dependently suppresses mechanical allodynia after chemotherapy, nerve injury, and diabetic neuropathy, but this blockade is abrogated in Tlr5-deficient mice. In vivo electrophysiology demonstrated that co-application of flagellin/QX-314 selectively suppressed A-fiber conduction in naive and chemotherapy-treated mice. TLR5-mediated A-fiber blockade, but not capsaicin-mediated C-fiber blockade, also reduced chemotherapy-induced ongoing pain without impairing motor function. Finally, flagellin/QX-314 co-application suppressed sodium currents in large-diameter human DRG neurons. Thus, our findings provide a new tool for targeted silencing of A-fibers and neuropathic pain treatment.
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Toll-like receptors (TLRs) are typically expressed in immune and glial cells to mediate innate and adaptive immunity 8, 9 . Recent studies have shown that TLRs such as TLR3, TLR4, and TLR7 are also expressed in primary sensory neurons, especially C-fiber nociceptive neurons in the DRG, to regulate sensory functions such as pain and itch 10, 11 . To determine whether DRG expresses different TLRs, we first used quantitative PCR (qPCR) to analyze 12 TLRs in mouse DRGs. As shown in Supplementary Figure 1 , TLR1-TLR9 and TLR13, but not TLR11 and TLR12, were expressed by mouse DRGs. Surprisingly, we found a unique distribution pattern of TLR5 in DRG neurons. In situ hybridization revealed that Tlr5 mRNA is expressed in medium-to-large-diameter mouse DRG neurons that co-express neurofilament-200 (NF200), a marker for myelinated A-fibers 12 ( Fig. 1a) . Size frequency analysis revealed overlapping distribution patterns of Tlr5 mRNA-positive (Tlr5 + ) and NF200-immunoreactive (IR) neurons; both are present in medium-to-large neurons (Fig. 1b) . Quantitative analysis demonstrated that 22% and 26% of DRG neurons express Tlr5 and NF200, respectively, and that 20% of DRG neurons are positive for both Tlr5 and NF200. Further analysis showed that 91% of Tlr5 + neurons contain NF200 (Fig. 1c) , and vice versa, that 78% of NF200 + neurons express Tlr5. We also observed Tlr5 mRNA in a small portion of small-diameter neurons (Fig. 1a,c) . Within the Tlr5 + population, 7.2% of neurons express calcitonin gene related peptide (CGRP), a marker for peptidergic C-fibers and some Aδ fibers 13 , and 7.7% of neurons express tyrosine hydroxylase (TH), a marker for low-threshold C-fibers 14 , but only 0.5% neurons bind isolectin B4 (IB4), a marker for non-peptidergic C-fibers ( Fig. 1c and Supplementary Fig. 2) . Immunohistochemistry confirmed the expression of TLR5 protein in NF200-IR DRG neurons in wild-type mice (Fig. 1d) . TLR5-IR was lost in Tlr5-knockout (Tlr5 −/− ) mice, suggesting the selectivity of the TLR5 antibody (Fig. 1d) .
Next we investigated whether TLR5 protein is also present in axons and axonal terminals in peripheral (skin) and central (spinal cord) sites, as a result of anterograde axonal transport of TLR5 from DRG neuronal cell bodies. We observed marked TLR5 expression in NF200-IR A-fibers in Meissner corpuscle-like structures in the dermis of hind-paw glabrous skin (Fig. 1e) . We also found some TLR5 + and NF200 + double-labeled nerve fibers at the base of hair follicles, but we saw no labeling near Merkel cells (Supplementary Fig. 3a-c) .
A-and C-fibers project to distinct laminae of the spinal dorsal horn: unmyelinated C-fibers project to the superficial layers (laminae I and II), and thin myelinated Aδ-fibers project to laminae I and V, whereas Aβ-fibers terminate in the deep laminae (III-V) 15 . TLR5-IR was only found in axonal terminals that co-express NF200 in the deep layers (Fig. 1f) . We observed no co-localization with CGRP in central terminals (Supplementary Fig. 3d ). There is less labeling of Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade TLR5-IR fibers in the skin than in the spinal cord, in part owing to the lower sensitivity of the antibody in skin tissue. Given the unique peripheral projection to Meissner corpusclelike structures in glabrous skin and central projections to the deep laminae of the dorsal horn, the TLR5-IR A-fibers should be primarily Aβ-fibers 15 .
QX-314 is a positively charged, membraneimpermeable lidocaine derivative (molecular weight: 263 Da). Binshtok et al. 16 previously demonstrated that co-application of QX-314 and the C-fiber-specific activator capsaicin (QX-314/capsaicin) results in neuronal entry of QX-314 through the ion channel TRPV1, leading to a functional blockade of C-fibers and subsequent pain relief. Activation of certain G protein-coupled receptors (GPCRs) also causes QX-314 influx through TRPV1 or TRPA1 and blockade of C-fibers via GPCR-TRPV1/A1 interactions 17 . Given the selective expression of TLR5 in A-fibers and the previously demonstrated coupling of TLRs with ion channels (for example, TLR7 with TRPA1 (ref. 18)), we hypothesized that activation of TLR5 might cause QX-314 entry and functional blockade of A-fibers when TLR5 is coupled with some ion channel. Flagellin, a principal component of bacterial flagella, is one of the best-studied TLR5 ligands 8, 19 . To assess whether flagellin can cause neuronal entry of QX-314, we recorded evoked transient sodium currents in dissociated primary cultures of mouse large-diameter A-fiber (>30 µm) and small-diameter C-fiber (<25 µm) DRG neurons via in vitro patch clamp electrophysiology. Co-application of flagellin (10 ng/ml, ~0.3 nM) with QX-314 (5 mM (ref. 16)) produced a substantial inhibition of sodium currents in A-fiber but not in C-fiber neurons (Fig. 2a) . This effect was also time dependent, with partial inhibition at 5 min and maximal inhibition at 10 min after the co-application, whereas flagellin or QX-314 alone produced no effects (Fig. 2b,c and Supplementary  Fig. 4a,b) . Notably, this inhibition of sodium currents was compromised in neurons from Tlr5 −/− mice, suggesting a specific effect of flagellin on TLR5 (Fig. 2a,b) . In sharp contrast, co-application of capsaicin (1 µM) and QX-314 (5 mM) only blocked sodium currents in C-fiber but not A-fiber neurons (Supplementary Fig. 5a-c) .
Sodium channels are essential for the induction of action potentials in sensory neurons. We next investigated whether this method of A-fiber blockade might also suppress action potentials in DRG neurons. Co-application of flagellin/QX-314 blocked action potentials in wild-type but not Tlr5-deficient A-fiber neurons, confirming a TLR5-mediated mechanism (Fig. 2d) . The scaffold protein myeloid differentiation primary response 88 (MYD88) mediates canonical signaling of TLR5 to activate the NFκB pathway and is present in DRG neurons 20 . However, we found that the A-fiber blockade by flagellin/QX-314 was not compromised in Myd88 −/− A-fiber DRG neurons (Supplementary Fig. 5d,e) . Figure 1 TLR5 is co-localized with the A-fiber marker NF200 in DRG neurons, skin nerve fibers, and spinal cord axonal terminals in mice. (a) Co-localization of Tlr5 mRNA and NF200-IR in DRG neurons. Yellow, white, and blue arrows show double-labeled neurons, Tlr5 singlelabeled neurons, and NF200 single-labeled neurons, respectively. Control (sense probe) shows no signal. Scale bar, 100 µm. (b) Sizedistribution frequency of Tlr5 mRNA-positive (Tlr5 + ), NF200-IR (NF200 + ) neurons, and total neurons in DRG. A total of 2,238 neurons from three mice were counted. (c) The percentage of total DRG neurons expressing Tlr5, NF200, and both Tlr5 and NF200, and the percentage of Tlr5 + neurons expressing NF200, IB4, CGRP, and TH. A total of 1,320 Tlr5 + neurons from three mice were counted. (d) Co-localization of TLR5-IR and NF200-IR in DRG neurons. Note that the TLR5 staining is absent in Tlr5 −/− mice. Scale bar, 100 µm. (e) Co-localization (shown by arrows) of TLR5 and NF200 in glabrous skin of mouse hind paws. Scale bar, 100 µm. (f) Co-localization of TLR5 and NF200 in deep laminae of the spinal cord dorsal horn. Boxed region of the image on the left is enlarged in the images to the right. Scale bars, 100 µm.
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Apart from QX-314, we also examined flagellin-mediated neuronal entry of a larger fluorescent molecule, phallodin-rhodamine (molecular weight: 1,231 Da). Co-incubation of flagellin with phallodin-rhodamine (10 µM) resulted in entry to large DRG neurons, and phallodin-rhodamine fluorescence was correlated with QX-314-elicited inhibition of action potentials (Fig. 2e) . Co-application of flagellin with phallodin-rhodamine in whole DRG preparations also lead to phallodin-rhodamine influx into NF200 + A-fiber neurons, and this influx was absent in DRG preparations from Tlr5 −/− mice ( Supplementary Fig. 6a-e) .
To determine the translational potential of our observations in mice, we also examined the effects of flagellin/QX-314 in human DRG neurons, dissociated from postmortem L3-L5 DRGs of 4 non-diseased donors (a 67-year-old male, a 52-year-old female, a 50-year-old female, and a 29-year-old male). Notably, co-application of flagellin (30 ng/ml, 0.9 nM) and QX-314 (12 mM) time-dependently suppressed sodium currents in large-diameter A-fiber (55-80 µm) human DRG neurons without affecting the currents in small-diameter C-fiber neurons (30-50 µm; Fig. 2f ,g and Supplementary Fig. 4c,d) . Notably, co-application of flagellin/QX-314 produced consistent inhibition of sodium currents in large-diameter DRG neurons from different age and sex groups (Fig. 2g) . Size-distribution analysis indicated that in human DRGs, TLR5 is primarily expressed by large-diameter neurons that co-express NF-200 ( Supplementary Fig. 7a,b) .
To investigate A-fiber blockade in the peripheral axons, we conducted in vivo electrophysiology in anesthetized mice. Compound action potentials evoked by electrical stimulation of the hind paw were recorded from mouse sciatic nerves. Co-application of flagellin (0.3 µg, ~10 pmol) and QX-314 (2%, ~60 mM) by intraplantar injection produced a significant inhibition of Aβ-conduction, without affecting the conduction of Aα-and Aδ-fibers (Fig. 3a,b) . As a positive control, 2% lidocaine blocked the conduction of all types of fibers (Fig. 3a,b) . Peripheral neuropathy and neuropathic pain induced by chemotherapy agents is a key limiting factor of chemotherapy as an anti-cancer treatment 21 . We therefore tested the blocking effects of flagellin/QX-314 in a mouse model of chemotherapy-induced but not small diameters (<50 µm, C-fiber). *P < 0.05, two-way ANOVA. For control (no treatment) groups, n = 6 C-fiber neurons, n = 7 A-fiber neurons. For QX-314 + flagellin groups, n = 8 C-fiber neurons and n = 8 A-fiber neurons. Human DRG cultures were prepared from four donors. All data are expressed as mean ± s.e.m.
npg l e t t e r S nature medicine VOLUME 21 | NUMBER 11 | NOVEMBER 2015neuropathic pain. Notably, 1 week after treatment with the chemotherapy agent paclitaxel (PAX, 6 mg/kg, intraperitoneal (i.p.)), flagellin/QX-314 treatment inhibited the conduction of Aβ-fibers, but not that of Aα-and Aδ-fibers (Fig. 3c,d) . However, PAX did not change the pattern or percentages of TLR5 + and NF200 + neurons (Supplementary Fig. 8a ). Consistently, in DRG neurons obtained from PAX-treated mice, flagellin/QX-314 application only blocked sodium currents in large-but not small-diameter neurons (Supplementary Fig. 8b,c) .
Because the sodium ion channel Nav1.8-expressing afferents (C-and Aδ-fibers) are dispensable for the development of chemotherapy-induced mechanical allodynia 2 , we hypothesized that Aβ-fiber blockade would inhibit chemotherapy-induced mechanical allodynia. As previously reported 20 , systemic injection of PAX elicited a rapid (<1 d) and persistent (>3 weeks) mechanical allodynia, demonstrated by a reduction in hind-paw withdrawal thresholds in response to stimulation with von Frey hairs. Notably, intraplantar co-application of QX-314 (0.2%, ~6 mM) with flagellin (0.1, 0.3, and 0.9 µg; i.e., 3-28 pmol) produced a dose-dependent reversal of mechanical allodynia 1 week after the PAX injection; this reversal peaked at 0.5 h, was maintained at 3 h, and recovered at 24 h (Fig. 4a) . Intraplantar injection of flagellin alone did not reduce PAX-induced mechanical allodynia in WT (C57BL/6, Tlr5 +/+ ) mice (data not shown). For comparison, 2% lidocaine only produced a very transient (<30 min) reversal of PAX-induced mechanical allodynia (Supplementary Fig. 9a ) after recovery from initial motor impairment (<10 min). We further investigated PAX-induced neuropathic pain in WT and Tlr5 −/− mice. Compared with WT mice, both baseline pain and PAX-elicited mechanical allodynia were unaltered in Tlr5 −/− mice (Fig. 4b) . However, QX-314/flagellin application failed to inhibit mechanical allodynia in Tlr5 −/− mice (Fig. 4b) , although this A-fiber blockade reversed allodynia in Myd88 −/− mice ( Supplementary  Fig. 9b) . Hence, flagellin/QX-314 blocks mechanical allodynia via TLR5 but not MyD88. By contrast, C-fiber blockade by intraplantar co-application of QX-314 (0.2%) with capsaicin (10 µg, ~33 nmol (ref. 22) , which is 1,000 times higher than the flagellin dose for A-fiber blockade) had no effects on PAX-induced mechanical allodynia ( Fig. 4a and Supplementary Fig. 9c) . Local flagellin/QX-314 treatment is well tolerated by mice. Repeated applications of flagellin/ QX-314, once a day for 5 d, produced persistent inhibition of PAXelicited allodynia without showing signs of causing antinociceptive tolerance (Fig. 4c) . In addition, the repeated applications did not seem to affect the overall well-being of mice and did not cause local hind-paw inflammation (Supplementary Fig. 10 ).
Apart from evoked pain assessed by sensory stimuli-evoked paw withdrawal responses, chronic pain is also characterized by ongoing pain, which can be assessed by conditioned place preference (CPP) testing 23, 24 . In a two-chamber CPP test, A-fiber blockade by flagellin/QX-314 elicited significant CPP in PAX-treated mice, whereas C-fiber blockade by capsaicin/QX-314 had no effect ( Fig. 4d  and Supplementary Fig. 9d) . Thus, A-fiber but not C-fiber blockade can suppress chemotherapy-induced ongoing pain. However, motor function, assessed by the Rota-rod test, was not affected by either A-fiber or C-fiber blockade (Fig. 4e) .
Next, we compared the effects of A-fiber versus C-fiber blockade in other neuropathic pain models: a diabetic neuropathy model induced by streptozotozin (STZ) injection, and a nerve injury model produced by chronic constriction injury (CCI). Notably, capsaicinsensitive C-fiber nociceptors are not required for the development of STZ-induced mechanical allodynia 25 . Our results show that STZ-induced mechanical allodynia was reversed by co-application of intraplantar flagellin/QX-314, but not by co-application of capsaicin/QX-314 (Supplementary Fig. 9e ). CCI elicits long-lasting mechanical allodynia for >4 weeks (ref. 26 ), and we found that this allodynia was also reversed by flagellin/QX-314 in the maintenance phase between 2 and 4 weeks after CCI (Fig. 4f and Supplementary  Fig. 11a,b) . As expected, this reversal was compromised in Tlr5 −/− mice ( Supplementary Fig. 11a,b) . In contrast, capsaicin/QX-314-induced C-fiber blockade only had mild inhibition on CCI-induced mechanical allodynia, although this blockade effectively suppressed heat hyperalgesia (Fig. 4f and Supplementary Fig. 11c,d) .
Finally, we evaluated the distinct roles of A-and C-fiber blockade in baseline pain. Of interest, flagellin/QX-314 treatment in naive mice decreased withdrawal thresholds and caused mechanical hypersensitivity, whereas capsaicin/QX-314 treatment increased withdrawal thresholds, as previously reported 16 (Supplementary Fig. 12a,b) . The effects of A-fiber but not C-fiber blockade were abrogated by Tlr5 deletion (Supplementary Fig. 12a,b) . This result suggests that Aβ-fibers might have distinct roles in normal and neuropathic pain conditions, and it supports the 'gate control theory' that Aβ-fiber activation in normal conditions inhibits pain transmission 27 .
In summary, we have identified TLR5 as a new marker for Aβ-fibers that co-express NF200, not only in primary sensory neuronal somata but also in their peripheral fibers in Meissner corpuscle-like structures of glabrous skin and central terminals in npg l e t t e r S the deep dorsal horn. Consistently, a recent database from single-cell RNA-seq analysis of mouse DRG neurons also shows Tlr5 mRNA expression primarily in Aβ-fibers 28 . Activation of TLR5 via flagellin led to selective QX-314 entry into TLR5-expressing DRG neurons and subsequent functional blockade of Aβ-fibers. This finding satisfies a key demand by providing a research tool for studying the function of Aβ-fibers. Neuropathic pain in preclinical models is driven by spontaneous discharges in primary sensory neurons, which mainly occur in Aβ-fibers 3, 29, 30 . Clinical neuropathic pain is also maintained by primary afferent activities 31 . Remarkably, flagellin/QX-314-elicited Aβ-fiber blockade, but not capsaicin/QX-314-induced C-fiber blockade, reversed chemotherapy-and nerve injury-evoked mechanical allodynia and chemotherapy-induced ongoing pain (Fig. 4) . Future studies are needed to investigate how flagellin and TLR5 interaction can increase membrane permeability, and whether this membrane change requires another partner (for example, an ion channel or transporter). Although our data support an important role for Aβ-fibers in sustaining neuropathic pain, we should not exclude the contributions of C-fibers and Aδ fibers, because (i) capsaicin-sensitive C-fibers are implicated in mechanical allodynia and ongoing pain 23 (but also see refs. 1-3,32); (ii) low-threshold C-mechanoceptors and Aδ-mechanoceptors may modulate mechanical hypersensitivity and allodynia 14, [33] [34] [35] ; and (iii) a small portion of Tlr5 + fibers could be TH + low-threshold C-fibers and CGRP + C-and Aδ-fibers. Furthermore, TLR5 could be expressed in CGRP-negative Aδ fibers. Future study is also required to characterize TLR5 expression in different afferent fibers when new tools such as Tlr5-GFP mice become available. However, our in vivo electrophysiology data suggest that the conduction of Aα-and Aδ-fibers is not affected by TLR5-mediated blockade (Fig. 3) , indicating limited expression of TLR5 in these A-fibers. Notably, in neuropathic pain conditions the 'gate' is already open, as a result of disinhibition in the spinal cord pain circuit. Therefore, Aβ-fiber stimulation could be sufficient to generate mechanical allodynia in neuropathic pain conditions 36, 37 . Our findings suggest that development of TLR5-mediated Aβ-fiber blockade will lead to novel therapies for treating mechanical allodynia and ongoing pain, the cardinal symptoms of clinical neuropathic pain. In support of this notion, co-application of flagellin and QX-314 also effectively blocked sodium currents in large-but not small-diameter human DRG neurons. It is worth mentioning that unlike lipopolysaccharide, flagellin is well tolerated by animals 38 and shows antitumor activity in immune therapy 39 . Given the high potency of flagellin (low-nanomolar range, versus the micromolar range of capsaicin) to deliver QX-314 into Aβ-fibers, local treatment of flagellin, together with QX-314, via intradermal or perineural routes at low doses, should be safe and feasible.
MeTHoDs
Methods and any associated references are available in the online version of the paper. Reagents. We purchased capsaicin, QX-314, phallodin-rhodamine, lidocaine, streptozotozin, and paclitaxel from Sigma-Aldrich, and we purchased flagellin from InvivoGen.
Animals. Knockout Tlr5 −/− and Myd88 −/− mice and corresponding WT control mice (C57BL/6 background) were purchased from Jackson Laboratories and maintained at the Duke animal facility. All the knockout mice were viable and showed no developmental defects. Young mice (4-6 weeks of both sexes) were used for electrophysiological studies in DRG neurons. Adult male mice (8-10 weeks) were used for behavioral and pharmacological studies. Male CD1 mice (8-10 weeks, Charles River) were also used for some behavioral and pharmacological studies. Mice were group-housed on a 12-h light/12-h dark cycle at 22 ± 1 °C with free access to food and water. No statistical method was used to predetermine sample size. No randomization was applied to the animal experiments. Sample sizes were chosen based on our previous studies on similar tests 11, 18, 20, 24 . All the animal procedures were approved by the Institutional Animal Care and Use Committee of Duke University. Animal experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Animal models of pain and drug injection. Intraperitoneal (i.p.) injection of paclitaxel (PAX, 6 mg/kg for a single injection or 2 mg/kg for multiple injections at days 0, 2, 4, and 6) was given to generate chemotherapy-associated neuropathic pain 20 . Both CD1 mice (males, for dose-response experiment) and C57BL/6 mice (males, WT and Tlr5 −/− ) were used. To produce streptozotocin (STZ)-induced diabetic neuropathy, male CD1 mice received a single intraperitoneal injection of STZ (75 mg/kg), as previously reported 40 .
To produce trauma-induced neuropathic pain model, we performed chronic constriction injury (CCI) in male C57BL/6 mice under isoflurane anesthesia 24, 26 . For intraplantar injection, drugs were injected using a Hamilton microsyringe (Hamilton) with a 30-gauge needle. Neuropathic pain behaviors were tested 1 week after STZ injection, 2 and 4 weeks after CCI, and 1 week after PAX injection.
Quantitative real-time RT-PCR. DRG tissues were rapidly isolated in RNase-free conditions. Total RNAs were extracted using RNeasy Plus Mini kit (Qiagen). Quantity and quality of the eluted RNA samples were verified by using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Total RNAs (0.5 µg) were reverse-transcribed using the QuantiTect Reverse Transcription Kit according to the manufacturer's protocol (Qiagen). Specific primers included were designed using IDT SciTools Real-Time PCR web tool and ordered from IDT (Integrated DNA Technologies). The sequences of the mouse TLR primers are described in Supplementary Table 1. We performed gene-specific mRNA analyses using the Bio-Rad CFX96 Real-Time RT-PCR system (Bio-Rad). Quantitative PCR amplification reactions contained the same amount of reverse transcription (RT) product, including 7.5 µl of Kapa SYBR Fast Bio-Rad iCycler 2X qPCR Master Mix (Kapa Biosystems) and 200 nM forward and reverse primers in a final volume of 15 µl. The thermal cycling conditions comprised 3 min of polymerase activation at 95 °C, 45 cycles of 10 s of denaturation at 95 °C, and 30 s of annealing and extension at 60 °C, followed by a DNA melting curve for the determination of amplicon specificity. The expression level of the target mRNA was normalized to expression of GAPDH mRNA and analyze by the standard 2 −∆∆CT method 41 .
In situ hybridization. Digoxigenin (DIG)-labeled RNA probes were used for in situ hybridization. For the TLR5 antisense probe, the mouse cDNA fragment was amplified by PCR with the antisense primer containing the T7 promoter sequence. The sequences of the primers for antisense probe were as follows: TLR5-F, 5′-TAACGAGTTCGTCTGCAACTGT-3′; TLR5-R, 5′-GCGTAATACGACTCACTATAGGGACCCTCTGATGGTCTCATGTCT-3′. The sense probe was included as control. For the TLR5 sense probe, the same mouse cDNA fragment was amplified by PCR with the sense primer containing the T7 promoter sequence instead. In vitro transcription was then performed from the PCR-amplified template using T7 RNA polymerase (Roche) with DIG-UTP (Roche) for the synthesis of the antisense and sense probes. 20-µm DRG sections were used for in situ hybridization as we previously described 42 . Pre-hybridization, hybridization and washing were performed according to standard methods 42 . Sections were then incubated with alkaline phosphatase conjugated anti-DIG (1:3500; Roche) and mouse anti-NF200 (1:1,000, mouse, N0142, Sigma), or CGRP antibody (1:1,000, guinea pig, T-5027, Peninsula), or TH antibody (1:1,000, Rabbit, AB152, EMD Millipore) overnight at 4 °C. After washing, the in situ signals were developed with Fast Red substrate and immunostaining signals were detected with Alexa Fluor 488-anti-mouse IgG (Molecular Probes, 1:1,000) or FITC-conjugated secondary antibodies (1:400; Jackson ImmunoResearch) or Alexa Fluor 488-conjugated IB4 (Molecular Probes, I21411, 1:400). For quantification, four or five DRG sections from each mouse were selected, and three mice were analyzed in each group. To determine the percentage of labeled neurons, the number of positive neurons was divided by the total number of neurons. Images were analyzed with NIH ImageJ software or Adobe PhotoShop.
Immunohistochemistry. After appropriate survival times, animals were deeply anesthetized with isoflurane and perfused through the ascending aorta with PBS, followed by 4% paraformaldehyde. After the perfusion, the L4-L5 spinal cord segments and DRGs were removed and postfixed in the same fixative overnight. Human DRGs from non-diseased donors were also postfixed with 4% paraformaldehyde overnight. Spinal cord sections 15 µm or 30 µm for free-floating) and DRG sections (10 µm) were cut in a cryostat. Hind-paw glabrous and hairy skins were also collected, postfixed in Zamboni's fixative solution, and cut in a cryostat (30 µm, free-floating). The sections were first blocked with 2% BSA for 1 h at room temperature. The sections were then incubated overnight at 4 °C with the following primary antibodies: TLR5 antibody (1:300, rabbit, Santa Cruz), NF200 (1:1,000, mouse, N0142, Sigma), Cytokeratin 20 (1:40, mouse, M701929-2, Dako), and CGRP antibody (1:1,000, guinea pig, T-5027, Peninsula). The sections were then incubated for 2 h at room temperature with cyanine 3 (Cy3)-or FITC-conjugated secondary antibodies (1:400; Jackson ImmunoResearch). For double immunofluorescence, sections were incubated with a mixture of polyclonal and monoclonal primary antibodies, followed by a mixture of Cy3-and FITC-conjugated secondary antibodies. The stained and mounted sections were examined with a Nikon fluorescence microscope, and images were captured with a charge-coupled device (CCD) Spot camera. Some sections were also examined under a Zeiss 510 inverted confocal microscope. To confirm the specificity of the TLR5 antibody, DRG, skin, and spinal cord sections from Tlr5 −/− mice were also immunostained. For quantification, four or five sections from each DRG were selected and four animals were analyzed in each group. To determine the percentage of labeled neurons, the number of positive neurons was divided by the total number of neurons. Images were analyzed with NIH ImageJ software or Adobe PhotoShop.
Primary cultures of mouse DRG neurons. We aseptically removed DRGs from 4-7-week-old mice of both sexes and digested the tissues with collagenase (1.25 mg/ml, Roche) and dispase II (2.4 units/ml, Roche) for 90 min, followed by 0.25% trypsin for 8 min at 37 °C (ref. 43) . We plated cells on glass coverslips coated with poly-d-lysine and laminin and grew them in a Neurobasal defined medium (with 2% B27 supplement) in the presence of 5 µM AraC, at 37 °C, with 5% CO 2 /95% air for 24 h before experiments.
Dye treatment in whole-mount DRGs and dissociated DRG neurons of mice. As previously described 44 , The L4-L5 whole-mount DRGs were carefully removed from the vertebral column and placed in cold oxygenated artificial cerebrospinal fluid (ACSF). The connective tissue was gently removed under a microscope and the ganglia were digested with a mixture of 1.0 mg/ml protease and 1.6 mg/ml collagenase (Sigma) for 30 min at 37 °C. DRG was transferred into a holding chamber containing normal Mg 2+ -free ACSF bubbled with 95% O 2 and 5% CO 2 at room temperature for 3 h. DRGs were incubated with 1 µM phallodin-rhodamine (Sigma) and 10 ng/ml flagellin for 15 min at 37 °C after the transferred into a holding chamber at room temperature for 1 h for removing nonspecific binding. DRGs were then fixed by 4% formalin and processed for immunohistochemistry as described above. In addition, dissociated DRG neurons were also treated with 10 µM phallodin-rhodamine npg
